Remicade Fc Gamma Receptor Binding Assays

BioOutsource provides a comprehensive portfolio of off-the-shelf Fc-Gamma Receptor (FcR) binding assays for Remicade by Surface Plasmon Resonance using the Biacore T-200 or 4000. These Remicade Fc Receptor binding assays can be used to rapidly accelerate development and manufacture of biosimilar Remicade in a cost effective manner. Our assays are used to support Remicade biosimilar process development, assessing material produced from different clones, different production processes or prepared in different formulations. We offer industry leading Remicade characterization services and these can be adapted to suit your product, as required.

The Fc-Gamma Receptors (FcR) are members of the immunoglobulin super family and play a critical role in the function of Remicade (infliximab). The Fc-Gamma Receptors (FcR) can be divided into three types: Fc-Gamma Receptor I (FcRI/CD64), Fc-Gamma Receptor II (FcRII/CD32) and Fc-Gamma Receptor III (FcRIII/CD16). Both the FcRII and FcRIII can be further divided into FcRIIa/FcRIIb and FcRIIIa/FcRIIIb. Historically, these receptors have been categorized based upon their affinity for specific IgG subclasses and whether their binding initiates activating or inhibitory signals. Following binding of Remicade (infliximab) to TNF-Alpha, the subsequent binding of the FcRs is crucial step for the initiation and control of cell-mediated effector functions of the immune system. Whilst FcRI is capable of binding monomeric IgG with high affinity and both FcRII and FcRIII have the capacity to bind IgG complexes and the binding can be affected by genetic polymorphism of the receptors as well as different glycosylation patterns in the Fc region of the Remicade.

The Remicade Fc-Gamma Receptor assays offered by BioOutsource are performed using the Biacore T200 or 4000, which are versatile, label-free systems with exceptional sensitivity. The Biacore T200 is the most sensitive SPR instrument available from GE Healthcare, and provides the optimal platform for evaluating both high affinity Fab binding characterization as well as Fc-Gamma Receptor binding, whereas the 4000 balances high levels of sensitivity with greater sample throughput. The following Remicade (infliximab) Fc-Gamma Receptor assays are offered by BioOutsource:

  • Remicade Fc-Gamma Receptor I (FcRI) binding assay by SPR
  • Remicade Fc-Gamma Receptor IIa (FcRIIa) binding assay by SPR
  • Remicade Fc-Gamma Receptor IIb (FcRIIb) binding assay by SPR
  • Remicade Fc-Gamma Receptor IIIa (V) (FcRIIIa V) binding assay by SPR
  • Remicade Fc-Gamma Receptor IIIa (F) (FcRIIIa F) binding assay by SPR
  • Remicade Fc-Gamma Receptor IIIb (FcRIIIb) binding assay by SPR

Sign-up to receive 3 tips on improving
speed to clinic for biosimilars

Sign-up to receive 3 tips on improving
speed to clinic for biosimilars

* you agree to receive emails with tips, news, insights and quizzes.